Michael-Robin Witt

Gabather's CEO Michael-Robin Witt in BioStock's studio.

BioStock Investor Pitch: Gabather

Gabather aims to improve the treatment of neuropsychiatric disorders by developing drugs aimed at treating a wide range of...

BioStock TV
Gabather - alzheimer's disease

Gabather aims to impact the neurodegeneration field

Neurodegeneration is a global societal crisis, affecting an...

Intervju
Gabather - alzheimer's disease

Gabather’s aims to impact the neurodegeneration field

Neurodegeneration is a global societal crisis, affecting an...

Intervju
Upwards

Gabather approaching initial target engagement study results

Gabather's target engagement study with the lead candidate...

Intervju

BioStock Studio: Gabather gives clinical trial update

Gabather’s top candidate GT-002 for treating psychiatric or...

BioStock TV
Intervju

Q4 report points to progress in the clinic for Gabather

Last week, Gabather published its 2020 year-end report,...

Gabather – focus on CNS diseases

Diseases of the central nervous system (CNS) and...